MAIA Biotechnology, Inc. Income (Loss) from Continuing Operations before Income Taxes, Domestic
MAIA Biotechnology, Inc. (MAIA) reported Income (Loss) from Continuing Operations before Income Taxes, Domestic of -$22.18 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-23.
Financial Statements › Income Statement › Pre-tax Income
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic · last filed 2026-03-23
- MAIA Biotechnology, Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2025 was -$22.18M.
- MAIA Biotechnology, Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2024 was -$23.12M.
- MAIA Biotechnology, Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2023 was -$19.60M.
- MAIA Biotechnology, Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2022 was -$15.30M.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month |
|---|---|
| 2025-12-31 | -$22.18M 10-K · filed 2026-03-23 |
| 2024-12-31 | -$23.12M 10-K · filed 2026-03-23 |
| 2023-12-31 | -$19.60M 10-K · filed 2024-03-21 |
| 2022-12-31 | -$15.30M 10-K · filed 2024-03-21 |
| 2021-12-31 | -$12.50M 10-K · filed 2023-03-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |